Payment overview · 2025
General Payments
$11,878.68
85 reported records · 39 companies
Healthcare provider profile · identity verified
Ameet P Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ST PETERSBURG, FL · NPI 1548623903
Verified facts
What the public records show
CMS Open Payments records show Ameet P Patel, MD received $11,878.68 in general payments during 2025 across 85 reported records.
AstraZeneca UK Limited accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jakafi.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REZUROCK as an associated drug or biological on 17 records involving 14 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rezurock by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jakafi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
SANOFI US SERVICES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REZUROCK as an associated drug or biological on 28 records involving 14 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rezurock by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca UK Limited | Unresolved — no canonical attribution shown | $4,020.00 | 33.8% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $3,526.49 | 29.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $2,318.96 | 19.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $166.04 | 1.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $146.50 | 1.2% | 3 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $145.40 | 1.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.36 | 1.2% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $134.97 | 1.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $131.11 | 1.1% | 5 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $124.13 | 1.0% | 5 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $121.21 | 1.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $83.43 | 0.7% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $55.84 | 0.5% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $54.61 | 0.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.91 | 0.5% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $53.33 | 0.5% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $52.24 | 0.4% | 5 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $50.63 | 0.4% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $45.62 | 0.4% | 1 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $33.51 | 0.3% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $30.43 | 0.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.11 | 0.2% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.87 | 0.2% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $25.72 | 0.2% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $25.53 | 0.2% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $25.05 | 0.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.68 | 0.2% | 1 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $23.15 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.13 | 0.2% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $22.95 | 0.2% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $21.73 | 0.2% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $20.74 | 0.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.91 | 0.2% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.63 | 0.2% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $17.93 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.46 | 0.1% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $16.33 | 0.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.97 | 0.1% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $9,183.60 | 4 |
| Food and Beverage | $2,660.02 | 80 |
| Education | $35.06 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARVYKTI Normalized: carvykti |
Biological, Drug | Janssen Scientific Affairs, LLC, Legend Biotech USA Inc. | $3,552.21 | 8 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $2,153.02 | 4 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $169.29 | 7 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $166.04 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $145.40 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological, Drug | Blueprint Medicines Corporation, SANOFI US SERVICES INC. | $139.14 | 2 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $124.58 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $104.75 | 4 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $95.34 | 4 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $60.41 | 3 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $55.84 | 2 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $55.50 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $53.33 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $52.24 | 5 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $50.63 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $47.14 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $46.91 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $45.64 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $45.62 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $42.41 | 4 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $41.56 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $30.43 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Merck Sharp & Dohme LLC | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma US Inc | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| BELEODAQ Normalized: beleodaq |
Drug | Acrotech Biopharma Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| KYPROLIS Normalized: kyprolis |
Drug | Amgen Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| Afstyla Normalized: afstyla |
Biological | CSL Behring | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Idelvion Normalized: idelvion |
Biological | CSL Behring | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | REZUROCK open payments reported associated product |
CMS Open Payments — General Payments 17 supporting records · 14 recipient NPIs · example record 1233208487 |
Rezurock · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| SANOFI US SERVICES INC. Exact reporting entity; no affiliate inference |
2025 | REZUROCK open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 14 recipient NPIs · example record 1233223313 |
Rezurock · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acyclovir | Acyclovir | 77 | 30 |
| Valacyclovir | Valacyclovir Hcl | 52 | 19 |
| Ninlaro | Ixazomib Citrate | 43 | suppressed |
| Eliquis | Apixaban | 41 | 11 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Gabapentin | Gabapentin | 33 | 13 |
| Revlimid | Lenalidomide | 32 | suppressed |
| Dexamethasone | Dexamethasone | 31 | 14 |
| Fluconazole | Fluconazole | 29 | 16 |
| Furosemide | Furosemide | 27 | 11 |
| Penicillin V Potassium | Penicillin V Potassium | 27 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 16 |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Brukinsa | Zanubrutinib | 21 | suppressed |
| Dapsone | Dapsone | 21 | suppressed |
| Prednisone | Prednisone | 21 | 15 |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 19 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Jaypirca | Pirtobrutinib | 12 | suppressed |
| Rezurock | Belumosudil Mesylate | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,878.68 · 85 records | AstraZeneca UK Limited | ADCETRIS, AKEEGA, AYVAKIT, Afstyla, BALVERSA, BELEODAQ, BESREMI, BRAFTOVI, CARVYKTI, DARZALEX, ELREXFIO, ENHERTU, EPKINLY, ERLEADA, IBRANCE, IMBRUVICA, IMFINZI, INQOVI, Idelvion, JAKAFI, JEMPERLI, KEYTRUDA, KISQALI, KYPROLIS, LIBTAYO, LONSURF, LORBRENA, LUTATHERA, LYNPARZA, Lenvima, MEKTOVI, MONJUVI, OGSIVEO, OJJAARA, OPDIVO, Orserdu, PLUVICTO, REBLOZYL, RYTELO, SARCLISA, SCEMBLIX, TALVEY, TECVAYLI, TUKYSA, Tecentriq, Trodelvy, ULTOMIRIS, Vonjo, WAYRILZ, Xospata, Yescarta, ZEJULA, ZEPZELCA, ZYNLONTA, ZYNYZ, clonoSEQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jakafi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error